China Pharma Univ. STING compound X41

China Pharma Univ. STING compound X41: sourced facts only. name: "Systematic optimization yielded the candidate compound X41, which exhibits potent STING agonist activity and favorable drug-like properties." [PMID:41633117]; target: "Systematic optimization yielded the candidate compound X41, which exhibits potent STING agonist activity and favorable drug-like properties." [PMID:41633117]; developer: "State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China." [PMID:41633117]; modality: "In this study, we developed a series of benzofuran derivatives as novel non-nucleotide STING agonists through structure-based drug design strategies." [PMID:41633117]; stage: "In the MC38 syngeneic tumor model, oral administration of X41 (50 mg/kg) achieved substantial tumor growth inhibition (TGI = 88.04 %), while intraperitoneal dosing (20 mg/kg) induced complete tumor regression in 50 % of the treated mice." [PMID:41633117]